PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
These re-agent and diagnostic test kits come with 99.7% accuracy
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
The product is expected to be launched in December 2023
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Receives registration of Valganciclovir powder for oral solution in Germany
Leading USA based genetic testing brand officially enters the Indian market
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
Subscribe To Our Newsletter & Stay Updated
